122 related articles for article (PubMed ID: 24238791)
21. Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.
Lim YS; Lee JY; Lee D; Shim JH; Lee HC; Lee YS; Suh DJ
Antimicrob Agents Chemother; 2013 Jul; 57(7):3369-74. PubMed ID: 23650172
[TBL] [Abstract][Full Text] [Related]
22. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
23. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
24. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
Park JG; Park SY
Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
[TBL] [Abstract][Full Text] [Related]
25. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
Wang JC; He LL; Chen Q
Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
Huang ZB; Zhao SS; Huang Y; Dai XH; Zhou RR; Yi PP; Chen RC; Li WT; Zhang BX; Li N; Fan XG
Clin Ther; 2013 Dec; 35(12):1997-2006. PubMed ID: 24238791
[TBL] [Abstract][Full Text] [Related]
27. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
Sheng YJ; Liu JY; Tong SW; Hu HD; Zhang DZ; Hu P; Ren H
Virol J; 2011 Aug; 8():393. PubMed ID: 21824397
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis.
Liu F; Wang X; Wei F; Hu H; Zhang D; Hu P; Ren H
Virol J; 2014 Mar; 11():59. PubMed ID: 24673792
[TBL] [Abstract][Full Text] [Related]
29. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients.
Dienstag JL; Wei LJ; Xu D; Kreter B
Clin Drug Investig; 2007; 27(1):35-49. PubMed ID: 17177578
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.
Chen EQ; Wang LC; Lei J; Xu L; Tang H
Virol J; 2009 Oct; 6():163. PubMed ID: 19818142
[TBL] [Abstract][Full Text] [Related]
31. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
Woo G; Tomlinson G; Nishikawa Y; Kowgier M; Sherman M; Wong DK; Pham B; Ungar WJ; Einarson TR; Heathcote EJ; Krahn M
Gastroenterology; 2010 Oct; 139(4):1218-29. PubMed ID: 20600036
[TBL] [Abstract][Full Text] [Related]
32. Adefovir dipivoxil in chronic hepatitis B infection.
Yuen MF; Lai CL
Expert Opin Pharmacother; 2004 Nov; 5(11):2361-7. PubMed ID: 15500383
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis.
Zhao P; Liu W; Zhao J; Guan Q
Virol J; 2011 Feb; 8():75. PubMed ID: 21342505
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
